Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wuling capsule plus nucleoside analogues in chronic hepatitis B hypoviremia
ChiCTR2200062623Phase 4Not yet recruiting
- Sponsor
- The Third Hospital of Hebei Medical University
- Start
- May 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of wulingshen in Chronic Hepatitis B (CHB) (2 arms), sponsored by The Third Hospital of Hebei Medical University. Primary endpoints: Serum HBV DNA load and Liver function tests (ALT, AST, GGT, ALP, TBIL, DBIL). Planned start May 2021; status: not yet recruiting.
02
Drugs
wulingshen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2200062623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062623.